

FOR IMMEDIATE RELEASE:

Integral Announces Capital Participation in the Blood Purification Business of Asahi Kasei Medical Co., Ltd.

Integral Corporation and the funds managed by it and its affiliates (collectively, "Integral") are pleased to announce that Integral has reached an agreement with Asahi Kasei Corp. ("Asahi Kasei") regarding capital participation in Asahi Kasei Medical Co., Ltd. ("Asahi Kasei Medical"), a wholly owned subsidiary of Asahi Kasei performing business in hemodialysis, therapeutic apheresis, etc. (collectively, "Blood Purification Business"). Asahi Kasei Medical will split its business other than the Blood Purification Business and transfer it to a separate company, and Integral will make an equity investment in Asahi Kasei Medical, which will perform the Blood Purification Business after the split.

With its 50-year history of development, manufacture, and sale of dialysis and therapeutic apheresis related products, Asahi Kasei Medical's Blood Purification Business has supplied a range of products that are highly evaluated by users both in Japan and overseas. Highly evaluated products consist of dialyzer with Vitamin E-interactive membrane, plasmapheresis products for intractable diseases, and the CryoSeal System for automated production of autologous fibrin sealant. In addition, Asahi Kasei Medical has launched new products and services to provide various values to the intensive care area, by leveraging rich experiences and know-how developed in the Blood Purification Business. Asahi Kasei Medical is believed to have its potential to contribute to more patients, their families, and healthcare professionals in Japan and overseas, and to achieve exponential growth in the future.

As an independent company specializing in medical devices as a healthcare infrastructure, the Blood Purification Business will continue to grow further and enhance their competitiveness by making decisions in a more timely and flexible manner and by investing human and financial resources in growing areas.

Integral will invest in Asahi Kasei Medical, and the voting rights of Asahi Kasei Medical will be 80% owned by Integral and 20% owned by Asahi Kasei. Integral will also acquire the remaining 20% from Asahi Kasei in about 2 years.

Integral will provide multifaceted supports in management, finance and business with Integral's management knowhow, "i-Engine" function and its network, so that Asahi Kasei Medical can become independent as soon as possible and achieve its next stage. The closing of this deal will be announced in our press release.



Please Contact Integral for Additional Information:

10F, GranTokyo South Tower 1-9-2, Marunouchi, Chiyoda-ku, Tokyo 100-6610 Japan

Integral Corporation

Tel: +81-3-6212-6100 Fax: +81-3-6212-6099

URL: <https://www.integralkk.com/en/>

About Integral

Integral (Representative Director: Reijiro Yamamoto) was founded in September 2007 as an independent Japanese private equity company investing in listed and unlisted companies in Japan. “Integral” stands for “integral calculus – accumulation over time” meaning that the company will strive to establish a relationship of highest trust with the management of invested companies, and will aim to accumulate the highest wisdom over time. Integral makes equity investments from a long-range perspective through its unique “hybrid investment” approach, utilizing both principal and fund money for investment. Subsequent to investment, the company will provide optimal support in terms of management and finance through the “i-Engine” corporate value enhancement team, and will collaborate with the invested company sharing the same objectives and time horizon and seeing eye-to-eye with its management. Integral aspires to be a trusted investment fund, contributing to society through the success of invested companies.